Shinichiro Ryuge1, Yuichi Sato2, Guo Qin Wang3, Toshihide Matsumoto4, Shi Xu Jiang5, Ken Katono1, Hayato Inoue6, Yukitoshi Satoh7, Noriyuki Masuda1. 1. Department of Respiratory Medicine, Kitasato University, Kanagawa, Japan. 2. Department of Molecular Diagnostics, School of Allied Health Sciences, Kitasato University, Kanagawa, Japan. Electronic address: yuichi@med.kitasato-u.ac.jp. 3. Kitasato Clinical Research Center, Kitasato University, Kanagawa, Japan. 4. Department of Cellular and Histo-Pathology, Graduate School of Medical Sciences, Kitasato University, Kanagawa, Japan. 5. Department of Pathology, Kitasato University, Kanagawa, Japan. 6. Department of Thoracic Surgery, National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan. 7. Department of Thoracic and Cardiovascular Surgery, School of Medicine, Kitasato University, Kanagawa, Japan.
Abstract
BACKGROUND: Nestin is a class 6 intermediate filament protein expressed in stem/progenitor cells during CNS development. Nestin expression has been detected in many kinds of tumors and was reported in a recent small-scale study in non-small cell lung cancer (NSCLC). We investigated the relationships between nestin expression and clinicopathologic parameters and determined its prognostic significance concerning survival in patients with resected NSCLC. METHODS: Nestin expression in tumor cells was studied immunohistochemically in 171 consecutive patients with NSCLC, and associations with clinicopathologic parameters were evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of nestin expression on survival. RESULTS: Nestin expression was observed in tumor cell samples in 27 of the 171 patients with NSCLC (15.8%). Nestin had only cytoplasmic expression. Clinicopathologically, nestin expression was significantly associated with squamous cell carcinoma (P = .001), poorer differentiation (P = .007), lymph node metastasis (P = .008), intratumoral vascular invasion (P = .003), intratumoral lymphatic invasion (P = .008), pleural invasion (P = .039), and poorer prognosis (P < .001). Multivariable analysis confirmed that nestin expression increased the hazard of death after adjusting for other clinicopathologic factors (hazard ratio, 2.75; 95% CI, 1.39-5.46). CONCLUSIONS: The present study suggests that nestin expression is a prognostic indicator of poorer survival probability for patients with resected NSCLC and may be used as a potential marker for select patients who should receive adjuvant chemotherapy.
BACKGROUND:Nestin is a class 6 intermediate filament protein expressed in stem/progenitor cells during CNS development. Nestin expression has been detected in many kinds of tumors and was reported in a recent small-scale study in non-small cell lung cancer (NSCLC). We investigated the relationships between nestin expression and clinicopathologic parameters and determined its prognostic significance concerning survival in patients with resected NSCLC. METHODS:Nestin expression in tumor cells was studied immunohistochemically in 171 consecutive patients with NSCLC, and associations with clinicopathologic parameters were evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of nestin expression on survival. RESULTS:Nestin expression was observed in tumor cell samples in 27 of the 171 patients with NSCLC (15.8%). Nestin had only cytoplasmic expression. Clinicopathologically, nestin expression was significantly associated with squamous cell carcinoma (P = .001), poorer differentiation (P = .007), lymph node metastasis (P = .008), intratumoral vascular invasion (P = .003), intratumoral lymphatic invasion (P = .008), pleural invasion (P = .039), and poorer prognosis (P < .001). Multivariable analysis confirmed that nestin expression increased the hazard of death after adjusting for other clinicopathologic factors (hazard ratio, 2.75; 95% CI, 1.39-5.46). CONCLUSIONS: The present study suggests that nestin expression is a prognostic indicator of poorer survival probability for patients with resected NSCLC and may be used as a potential marker for select patients who should receive adjuvant chemotherapy.
Authors: Farhan Saboor; Ansgar N Reckmann; Claudia U M Tomczyk; Dorothea M Peters; Norbert Weissmann; Andre Kaschtanow; Ralph T Schermuly; Tatyana V Michurina; Grigori Enikolopov; Dieter Müller; Andrea Mietens; Ralf Middendorff Journal: Eur Respir J Date: 2015-12-23 Impact factor: 16.671
Authors: Jun Wang; Baocheng Wang; Weipeng Zhao; Yan Guo; Hong Chen; Huili Chu; Xiuju Liang; Jingwang Bi Journal: PLoS One Date: 2012-12-20 Impact factor: 3.240
Authors: Tamara Mirzapoiazova; Nurbek Mambetsariev; Frances E Lennon; Bolot Mambetsariev; Joshua E Berlind; Ravi Salgia; Patrick A Singleton Journal: Front Oncol Date: 2015-07-21 Impact factor: 6.244